Page 46 - Sun Pharma News Today

With this funding, Mumbai-based Neodocs aims to double down its investments in existing products, particularly focusing on its kidney care and urinary tract infections (UTI) kit. It also plans to enhance its self-diagnosis offerings by introducing a finger-prick blood test product that will provide results on a smartphone.

The 30-share BSE Sensex declined by 354.21 points or 0.49 per cent to settle at 71,731.42 on fag-end selling.

Fresh foreign fund inflows also added to the positive momentum in equities

Stocks in news: Kotak Mahindra Bank: CCI approves acquisition of 70% stake in Kotak Mah General Insurance by Zurich Insurance Company Max Fin: IRDAI approves capital infusion of Rs 1,612 cr by Axis Bank, subject to approval from CCI Data Infrastructure: Axis Bank sold Rs 932.9 cr worth equity stake in the coAnahere Investment bought 6.06 cr shares at an average price of Rs

Benchmark Sensex fell back by 354 points on Monday due to selling in index major Reliance Industries, Bharti Airtel and Maruti amid weak trends from Asian and European markets. The 30-share BSE Sensex declined by 354.21 points or 0.49 per cent to settle at 71,731.42 on fag-end selling. During the

Motilal Oswal is bullish on Sun Pharma recommended buy rating on the stock with a target price of Rs 1635 in its research report dated January 31, 2024.

India VIX, the fear gauge, remained elevated at 15, suggesting that consolidation is likely to persist in the near future

Sensex closed 34.09 points or 0.05% higher at 72,152, and the Nifty shut shop 1.10 points or 0.01% up at 21,930. About 1,927 shares advanced, 1,329 declined, and 75 remained unchanged.

Indian generic drugmaker Lupin reported a bigger-than-expected rise in its third-quarter profit on Wednesday, helped by strong demand in its North American and domestic markets. ...

Semgalutide has almost 66 percent of the market share in the anti-obesity segment.